Awaiting development: Guidance and quality standards

Showing 191 to 200 of 335

Guidance and quality standards awaiting development
Title	Type
Orforglipron for managing overweight and obesity TS ID 12102	Technology appraisal guidance
Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472	Technology appraisal guidance
Osteoporosis	Quality standard
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]	Highly specialised technology
Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]	Technology appraisal guidance
Pain management (young people and adults)	Quality standard
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pancreatitis (including acute pancreatitis)	Quality standard
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865	Technology appraisal guidance
Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467	Technology appraisal guidance